Project Grant K08CA279908
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$263K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This K08 project grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to St. Jude Children's Research Hospital supports the recipient's research program focused on developing innovative cellular therapies to improve outcomes for pediatric patients with high-risk B-cell malignancies. The key products and services to be delivered under this $289,458 award from September 2024 to August 2029 include: Conducting a Phase I clinical trial (MEMCAR19) to evaluate an...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $588,330 to The Children's Hospital of Philadelphia (CHOP) to conduct research aimed at improving CD19 CAR T cell immunotherapy for pediatric patients with KMT2A-rearranged acute lymphoblastic leukemia (ALL). The key research activities under this 1-year award include investigating the combinatorial use of menin inhibitors (Aim 1) and MEK inhibitors (Aim 2) alongside...
This $230,947 K08 research grant from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support a pediatric oncologist's research on the role of the SLC46A3 gene as a biomarker for improving the efficacy of nanoparticle-based cancer therapies. The project aims to establish SLC46A3's function in phospholipid homeostasis and its impact on liposomal nanoparticle delivery in pediatric neuroblastoma, with the goal of validating SLC46A3 as a clinical biomarker to...
This is a Project Grant award from the National Cancer Institute (NCI), through the Cancer Research Manpower (CFDA 93.398) federal grant program. The $248,509 award will fund research to identify the cellular and cytokine initiators of chimeric antigen receptor T-cell (CAR-T) induced cytokine release syndrome (CRS), as well as the role of the inflammasome and complement in CAR-T induced immune effector cell associated neurotoxicity syndrome (ICANS). The research will be conducted at the...
The National Cancer Institute (NCI) awarded a $143,788 Project Grant under its Cancer Research Manpower (CFDA 93.398) program to The Broad Institute, Inc. to support research on genetic dependencies in KIAA1549-BRAF rearranged pediatric low-grade gliomas. The key objectives are to understand how the KIAA1549:BRAF fusion is activated, and why the POMT complex is a selective dependency in KIAA1549:BRAF-dependent cells. The 2-year project aims to test hypotheses related to the role of POMT...
The National Cancer Institute (NCI) awarded a $148,568 Project Grant under the Cancer Research Manpower Program (CFDA 93.398) to St. Jude Children's Research Hospital in Memphis, Tennessee. The goal of this 3-year project, with a start date of December 25, 2024 and end date of July 14, 2027, is to elucidate the mechanism by which a gene essential for rhabdoid tumor cell viability regulates chromatin function. The project will leverage CRISPR-Cas9 screening and molecular/genomic approaches to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $172,013 in funding to support the research efforts of a pediatric oncologist at the University of Colorado-Denver. The primary objectives are to complete ongoing clinical trials of the novel therapeutic agent inotuzumab ozogamicin for the treatment of relapsed and newly diagnosed pediatric acute lymphoblastic leukemia, as well as to lead the development of additional Children's...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, provides $1,197,216 to St. Jude Children's Research Hospital to advance the scientific understanding and treatment of pineoblastoma, a rare and aggressive pediatric brain tumor. The key objectives are to: (1) leverage single-cell transcriptome data and developmental atlases to delineate the cellular origins and molecular drivers of distinct...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,030,836 to The Children's Hospital Corporation (Boston Children's Hospital) to elucidate the molecular mechanisms underlying chemotherapy-induced neurotoxicity, with a focus on oxidative distress. The research aims to understand how the chemotherapeutic drug methotrexate causes damage to the choroid plexus and cerebrospinal fluid, leading to neurological impairments in pediatric...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is supporting research focused on understanding the role of IL-6/STAT3 signaling in the growth, metastasis, and immunosuppression of CIC-DUX4 fusion-positive sarcomas. The $593,028 award to the Beckman Research Institute of the City of Hope aims to: 1) define the critical role of IL-6/STAT3 signaling in tumor cells for CIC-DUX4 fusion sarcoma progression and metastasis, 2) examine the...